The one thing wrong with the science behind ELI-200 is that the competition will not really stand much of a chance of out gunning Elites ADF. That the FDA could potentially claim Elites ADF as their poster child in the war on prescription opioid abuse is not that far off from becoming a reality. And for all other big pharmaceuticals that is what is wrong with the science behind Elites technology.